Processes, compositions and agents are included for inhibiting corrosion in various substrates, for example metal substrates. Corrosion inhibitors include organometallic polymers such as metal-organic frameworks (MOFs), including compositions and processes comprising MOFs for inhibiting corrosion in metal substrates. In some aspects, a method of protecting a substrate from corrosion includes applying a protective composition including a corrosion inhibitor to the surface of a substrate, where the corrosion inhibitor includes a metal organic framework (MOF).

The present invention relates to indium alkoxide compounds preparable by reacting an indium trihalide InX.sub.3 where X=F, Cl, Br, I with a secondary amine of the formula R′.sub.2NH where R′=alkyl, in a molar ratio of 8:1 to 20:1 in relation to the indium trihalide, in the presence of an alcohol of the generic formula ROH where R=alkyl, to a process for preparation thereof and to the use thereof for production of indium oxide-containing or (semi)conductive layers.

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

##STR00001##

A perovskite compound represented by Formula 1, a thin layer including the perovskite compound, and an optoelectronic device including the perovskite compound:

[A][B.sup.1.sub.nB.sup.2.sub.(1-n)][X].sub.3.  Formula 1

In Formula 1, A may be at least one selected from a monovalent organic cation, monovalent inorganic cation, and combinations thereof; B.sup.1 may be a thulium (II) (Tm.sup.2+) ion; B.sup.2 may be at least one divalent inorganic cation, where B.sup.2 is free of (e.g., does not include) Tm.sup.2+; n may be a real number that satisfies 0<n≦1; and X may be at least one monovalent anion.

A lanthanide complex, method of forming and method of using the lanthanide complex as a near-infrared luminescent material are described. The complex includes at least one lanthanide ion and at least one polydentate ligand derived from a molecule having the general formula of Structure 2: ##STR00001## where: E represents a heteroatom or heteroatom-containing group and R.sub.1-R.sub.8 are independently selected from H, —OH, —NH.sub.2, —SO.sub.3H, —CO.sub.2H, halides, optionally substituted organic groups; and conjugated linking groups which link two of the polydentate ligands of Structure 2 together.

An MRI contrast composition includes a liposome and a europium metal complex disposed within the liposome. The europium metal complex includes a europium metal ion and a multi-dentate ligand selected from the group consisting of cryptands and thiacryptands and one or more counter-ions that balances a charge of the europium metal ion and the multi-dentate ligand, the europium metal ion being switchable between a 2+ and 3+ oxidation state. The contrast composition advantageously provides an oxidation-responsive dual-mode contrast agent because it would enhance either T.sub.1-weighted images or CEST images depending on the oxidation state of Eu.

The present disclosure relates generally to a process for the synthesis of 1,4,7,10-tetraazacyclododecane ligands, chelates, and derivatives thereof. In particular, the present disclosure is directed to a process for the synthesis of 1,4,7,10-tetraaza-1,4,7,10-tetrakis(carboxymethyl)cyclododecane (DOTA) ligands, corresponding DOTA-metal chelates, and various derivatives thereof.

A method for making organo-metal material involves providing a metal ion source in a medium that removes metal ions from the source and forms 1D metal-containing coordination polymers that self-assemble and precipitate as at least one of a 2D and 3D coordination polymer material that can be thermally treated to produce a porous metal oxide material.

A method of labelling biological molecules with .sup.18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilized to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.

The invention relates to metal complex compounds of the formula M.sub.k(L).sub.x(Y).sub.kz-nx, where the ligand L has the formula (I), and to metal complex compounds which include the reaction product of at least one salt or a complex of a transition metal or a main group metal element of the groups 13 to 15 and at least one 1,3-ketoamide. Such complex compounds are suitable in particular as catalysts for polyurethane compositions. The invention also relates to two-component polyurethane compositions including at least one polyisocyanate as the first component, at least one polyol as the second component, and at least one such metal complex compound as the catalyst. The invention additionally relates to different uses of the two-component polyurethane compositions.